JP2019520332A - Ｃｍｖエピトープ - Google Patents

Ｃｍｖエピトープ Download PDF

Info

Publication number
JP2019520332A
JP2019520332A JP2018561467A JP2018561467A JP2019520332A JP 2019520332 A JP2019520332 A JP 2019520332A JP 2018561467 A JP2018561467 A JP 2018561467A JP 2018561467 A JP2018561467 A JP 2018561467A JP 2019520332 A JP2019520332 A JP 2019520332A
Authority
JP
Japan
Prior art keywords
subject
apc
cmv
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018561467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520332A5 (cg-RX-API-DMAC10.html
Inventor
カンナ，ラジーブ
スミス，コーリー
Original Assignee
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ, ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ filed Critical ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
Publication of JP2019520332A publication Critical patent/JP2019520332A/ja
Publication of JP2019520332A5 publication Critical patent/JP2019520332A5/ja
Priority to JP2023020200A priority Critical patent/JP2023071724A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018561467A 2016-05-23 2017-05-23 Ｃｍｖエピトープ Pending JP2019520332A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023020200A JP2023071724A (ja) 2016-05-23 2023-02-13 Ｃｍｖエピトープ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340223P 2016-05-23 2016-05-23
US62/340,223 2016-05-23
PCT/IB2017/000849 WO2017203370A2 (en) 2016-05-23 2017-05-23 Cmv epitopes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023020200A Division JP2023071724A (ja) 2016-05-23 2023-02-13 Ｃｍｖエピトープ

Publications (2)

Publication Number Publication Date
JP2019520332A true JP2019520332A (ja) 2019-07-18
JP2019520332A5 JP2019520332A5 (cg-RX-API-DMAC10.html) 2020-07-02

Family

ID=60412168

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018561467A Pending JP2019520332A (ja) 2016-05-23 2017-05-23 Ｃｍｖエピトープ
JP2023020200A Pending JP2023071724A (ja) 2016-05-23 2023-02-13 Ｃｍｖエピトープ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023020200A Pending JP2023071724A (ja) 2016-05-23 2023-02-13 Ｃｍｖエピトープ

Country Status (7)

Country Link
US (2) US20200316119A1 (cg-RX-API-DMAC10.html)
EP (1) EP3463400A4 (cg-RX-API-DMAC10.html)
JP (2) JP2019520332A (cg-RX-API-DMAC10.html)
CN (1) CN109475579A (cg-RX-API-DMAC10.html)
AU (3) AU2017271136A1 (cg-RX-API-DMAC10.html)
CA (1) CA3025234A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017203370A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526766A (ja) * 2020-04-28 2023-06-23 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ ヒトサイトメガロウイルスポリエピトープワクチン組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
CA3100420A1 (en) * 2018-05-18 2019-11-21 The Council Of The Queensland Institute Of Medical Research Adoptive t-cell therapy for cmv infection and cmv-associated diseases
MX2021002702A (es) 2018-09-10 2021-05-12 Atara Biotherapeutics Inc Metodos para expandir celulas t del receptor de antigeno quimerico especificas de antigenos, composiciones y usos relacionados con las mismas.
US20260055195A1 (en) * 2019-10-09 2026-02-26 The Council Of The Queensland Institute Of Medical Research Targeting epha3 and uses thereof
CN111875698B (zh) * 2020-07-29 2021-11-05 广州呈源生物免疫技术有限公司 靶向hcmv的tcr及其获得方法和应用
KR102769935B1 (ko) * 2021-03-30 2025-02-19 한국과학기술원 펩타이드-mhc에 대한 t 세포 활성의 예측 방법 및 분석장치

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501076A (ja) * 1999-06-04 2003-01-14 フロリアン・ケルン ヒトｃｍｖに対するワクチン接種のためのペプチド
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10009341A1 (de) * 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
AU2012227280B2 (en) * 2004-11-29 2016-09-22 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
WO2006056027A1 (en) * 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
US20110136896A1 (en) * 2008-08-01 2011-06-09 Tong-Ming Fu Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
GB0917094D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
EP2812431B1 (en) * 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2013170305A1 (en) * 2012-05-16 2013-11-21 Adelaide Research & Innovation Pty Ltd Cellular vaccine and method of inducing an immune response in a subject
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
US9757446B2 (en) * 2014-03-17 2017-09-12 Flugen, Inc. Influenza virus vectors and uses therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501076A (ja) * 1999-06-04 2003-01-14 フロリアン・ケルン ヒトｃｍｖに対するワクチン接種のためのペプチド
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JDI, 2007, VOL.195, PP,1789-1798, JPN6022006768, ISSN: 0005054160 *
JOURNAL OF VIROLOGY, 1999, VOL.73, NO.10, PP.8179-8184, JPN6022006770, ISSN: 0005054161 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526766A (ja) * 2020-04-28 2023-06-23 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ ヒトサイトメガロウイルスポリエピトープワクチン組成物

Also Published As

Publication number Publication date
AU2023201279A1 (en) 2023-04-20
EP3463400A2 (en) 2019-04-10
AU2026203085A1 (en) 2026-05-21
CA3025234A1 (en) 2017-11-30
WO2017203370A2 (en) 2017-11-30
CN109475579A (zh) 2019-03-15
WO2017203370A3 (en) 2018-02-01
US20200316119A1 (en) 2020-10-08
EP3463400A4 (en) 2020-07-29
AU2017271136A1 (en) 2019-01-03
US20250127874A1 (en) 2025-04-24
JP2023071724A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
US20250127874A1 (en) Cmv epitopes
US10603380B2 (en) Chimeric antigen and T cell receptors and methods of use
JP7515209B2 (ja) 癌免疫療法用ｍｒ１制限ｔ細胞受容体
US12291559B2 (en) Compositions and methods for treating cancer
JP2025131713A (ja) Ｈｐｖ免疫療法
AU2024219637A1 (en) Adoptive t-cell therapy for cmv infection and cmv-associated diseases
JP2026031931A (ja) 標的化ｅｐｈａ３及びその使用
US20230381298A1 (en) Herpesvirus polyepitope vaccines
WO2025241005A1 (en) Enhanced chimeric antigen receptor t cell composition and method of use
WO2024206155A1 (en) Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
HK40073027A (en) Chimeric antigen and t cell receptors and methods of use
HK40040260A (en) Hpv immunotherapy
HK40003800B (en) Chimeric antigen and t cell receptors and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190129

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220822

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230213

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230228

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230330

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230404

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250213